HROW - Harrow Health Inc Stock Price, Fair Value and News

$44.52+4.35 (+10.83%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HROW Price Action

Last 7 days

7.8%

Last 30 days

23.8%

Last 90 days

23.0%

Trailing 12 Months

11.2%

HROW RSI Chart

HROW Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-330.57

Price/Sales (Trailing)

6.59

EV/EBITDA

46.65

Price/Free Cashflow

99.49

HROW Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HROW Fundamentals

HROW Revenue

Revenue (TTM)

250.0M

Rev. Growth (Yr)

45.44%

Rev. Growth (Qtr)

12.39%

HROW Earnings

Earnings (TTM)

-5.0M

Earnings Growth (Yr)

124.17%

Earnings Growth (Qtr)

-79.58%

HROW Profitability

EBT Margin

3.23%

Return on Equity

-10.69%

Return on Assets

-1.37%

Free Cashflow Yield

1.01%

HROW Investor Care

Shares Dilution (1Y)

3.99%

Diluted EPS (TTM)

-0.15

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	212.9M	227.7M	250.0M	0
2024	138.7M	154.1M	169.1M	199.6M
2023	92.6M	102.7M	114.2M	130.2M
2022	79.2M	84.3M	88.5M	88.6M
2021	52.5M	62.6M	66.9M	72.5M
2020	50.7M	45.2M	46.9M	48.9M
2019	44.8M	47.9M	49.9M	51.2M
2018	30.4M	34.1M	37.7M	41.4M
2017	0	22.4M	24.6M	26.8M
2016	0	13.1M	16.0M	19.1M
2015	3.2M	4.5M	6.8M	9.7M
2014	2.7M	2.3M	2.0M	1.7M
2013	3.7M	3.3M	3.0M	0
2012	0	0	0	4.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Harrow Health Inc

Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

CEO	Mr. Mark L. Baum J.D.
WEBSITE	harrowinc.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	217

Harrow Health Inc Frequently Asked Questions

What is the ticker symbol for Harrow Health Inc? What does HROW stand for in stocks?

HROW is the stock ticker symbol of Harrow Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Harrow Health Inc (HROW)?

As of Wed Dec 03 2025, market cap of Harrow Health Inc is 1.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HROW stock?

You can check HROW's fair value in chart for subscribers.

Is Harrow Health Inc a good stock to buy?

The fair value guage provides a quick view whether HROW is over valued or under valued. Whether Harrow Health Inc is cheap or expensive depends on the assumptions which impact Harrow Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HROW.

What is Harrow Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, HROW's PE ratio (Price to Earnings) is -330.57 and Price to Sales (PS) ratio is 6.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HROW PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Harrow Health Inc's stock?

In the past 10 years, Harrow Health Inc has provided 0.2 (multiply by 100 for percentage) rate of return.